Sat, Jan 31, 2015, 12:02 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • jacosa jacosa Jul 9, 2013 10:15 AM Flag

    Thinking about the pancreatic CA trial

    We should be getting topline fairly soon, so I'd like to speculate. First: QoL is more important to us than survival, because QoL applies to all toxic cancers while survival applies to pancreatic cancer specifically. I don't think the Street at large will see it that way. So I expect a survival success to be worth about $1.50 immediately, and a survival failure to cost about $0.75 (INCY isn't getting any value assigned from the prospects here). Benefits to both survival and QoL could easily lead to doubling of ruxo (it's still off-label) use within a year, so the initial jump might not be retraced. QoL only would generate almost as much use (And an immediate price drop), so it might be a nice buying opportunity. Most likely, such a partial success would also induce Incyte to look for a drug with the optimum mix of JAK type specificities (full success might also, but you can't do everything at once and there'd be a big push to justify a label expansion for Jakafi). Since complete failure would essentially be a non-event, I would expect the initial loss to be recovered within the month.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
79.71-1.63(-2.00%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
ImmunoGen, Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST